Kim Won Jun
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea.
Korean J Gastroenterol. 2024 Mar 25;83(3):94-101. doi: 10.4166/kjg.2024.016.
The prevalence of obesity with various complications is increasing rapidly in Korea. Although lifestyle modification is fundamental in obesity treatment, more effective treatment tools are required. Many advances in obesity treatment have been reported recently, including lifestyle modifications and pharmacological, endoscopic, and surgical treatments. Drugs with proven long-term efficacy and safety are preferred because management for obesity treatment is a long-term process. Currently, four medications are available for long-term use in Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate capsule, and Liraglutide. Recently, semaglutide and tirzepatide have been attracting attention because of their effectiveness and convenience, but they are not yet available in Korea. In addition, there are limitations such as the yo-yo effect when discontinuing the drug, long-term safety, and cost. Patients and medical staff must be aware of the advantages and side effects of each medication to ensure the successful treatment of obesity.
在韩国，伴有各种并发症的肥胖症患病率正在迅速上升。尽管生活方式的改变是肥胖症治疗的基础，但仍需要更有效的治疗手段。最近报道了肥胖症治疗方面的许多进展，包括生活方式的改变以及药物、内镜和手术治疗。由于肥胖症治疗是一个长期过程，因此首选具有长期疗效和安全性的药物。目前，韩国有四种药物可长期使用：奥利司他、纳曲酮/安非他酮缓释片、苯丁胺/托吡酯胶囊和利拉鲁肽。最近，司美格鲁肽和替尔泊肽因其有效性和便利性而备受关注，但在韩国尚未上市。此外，还存在停药时的溜溜球效应、长期安全性和成本等局限性。患者和医护人员必须了解每种药物的优缺点，以确保肥胖症的成功治疗。
